What AMP PD partners are saying


“Parkinson’s disease is a complex, progressive and heterogeneous disease, which is particularly difficult to treat,” said Rupert Vessey, President of Research and Early Development, Celgene Corporation. “Since every person is unique, a targeted approach may have the potential to bring highly effective therapies and high-value care to patients with this disease. The investments needed to discover and develop these life-enhancing medicines can substantially improve health outcomes, and reduce the cost of failing to appropriately target treatment, estimated to be tens of billions of dollars every year.”


“Parkinson’s disease requires new medicines,” said Min Li, Senior Vice President and Head of Neuroscience, GlaxoSmithKline. “Seeking insights into disease biomarkers by applying state of the art analytics in a collaborative partnership is an important pathway to meet this need. GSK is excited and proud to be part of this initiative to further evolve our understanding of disease and accelerate medicines to patients.”

The Michael J. Fox Foundation

"The Michael J. Fox Foundation, the National Institutes of Health, industry partners and thousands of research volunteers have built robust datasets and biosample banks ripe for inquiry with the latest technologies. Leveraging those previous investments and partnering together can move us faster toward greater understanding of Parkinson's and therapies to slow or stop disease, patients' greatest unmet need,” said Todd Sherer, Ph.D., Chief Executive Officer, The Michael J. Fox Foundation for Parkinson's Research.


“A challenge as big as Parkinson’s disease needs the collective focus of the entire R&D ecosystem. I’ve seen first-hand what we can accomplish when we come together with a common goal. Pfizer is proud to join the AMP PD and the effort to better understand the drivers of this devastating disease.” Mikael Dolsten, M.D., Ph.D., President of Worldwide Research and Development, Pfizer.


“We are excited to partner with other scientific leaders across the health care sector to advance the understanding of Parkinson’s disease,” said Tanya Fischer, MD, PhD, Global Project Head of Early Development for Parkinson’s Disease and Movement Disorders, Sanofi R&D. “We look forward to working together to help identify and validate new therapeutic targets and develop biomarkers to improve clinical trial design, with the goal being to accelerate the development of new treatment options for patients affected by this devastating disease.”


"There's a lot of rich data in these publicly-funded data sets that currently exist in siloed repositories, and our vision in creating this knowledge portal is to empower synthesis of these data to potentially generate new insights into Parkinson's Disease," stated Andy Conrad, Chief Executive Officer, Verily. "A platform that organizes complex molecular, clinical, imaging and, ultimately, biosensor data for easy research and querying does not yet exist, so this work is important and will take significant effort."

This page last reviewed on January 30, 2018